A dose of hope: CT1812 from Cognition proves its ability in Alzheimer’s Aβ…
Cognition Therapeutics Inc CGTX announces the publication of data from a Phase 1b SNAP study of CT1812 measuring Aβ oligomer displacement in Alzheimer’s disease Journal
Home » proves
Cognition Therapeutics Inc CGTX announces the publication of data from a Phase 1b SNAP study of CT1812 measuring Aβ oligomer displacement in Alzheimer’s disease Journal
When inventors need an NDA, what it actually protects, and the routine confidentiality habits that keep patent options open before filing.
Recovery after a serious car accident often takes weeks to months, while severe injuries may require a year or longer. The first 72 hours usually
As remote work becomes a permanent fixture of American employment, a new national study from John Foy & Associates uncovers the rising dangers hiding behind